Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf,and MEK
作者： Eli M. Wallace , Tammie C. Yeh , Ellen R. Laird , James F. Blake , Joseph Lyssikatos
关键词:
摘要: Approval of Gleevec and its demonstrated therapeutic value marked the full recognition kinase inhibitorsas a relevant means cancer treatment. A significant number inhibitors have recentlyentered clinical practice for treatment variety cancers many others are in advancedstages research. Among these several promising agents that act pathway initiateswith growth factor receptors EGFR/ErbB2 signals through Raf MEK to MAP ERK. Thischapter focuses on biological rationale, enzymatic pharmacological properties, statusof EGFR/ErbB2, Raf, MEK1/2. Coverage is given those compounds gainedapproval or being evaluated human trials.
springer.com
sci-hub.se 参考文章(107)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Ari Matthew Melnick, Alexander D. MacKerell, Gilbert Gerard Privé, Small molecule inhibitors of bcl6 ,(2007)
Bruce E. Johnson, Pasi A. Jänne, Epidermal Growth Factor Receptor Mutations in Patients with Non–Small Cell Lung Cancer Cancer Research. ,vol. 65, pp. 7525- 7529 ,(2005) , 10.1158/0008-5472.CAN-05-1257
Peter Blume-Jensen, Tony Hunter, Oncogenic kinase signalling. Nature. ,vol. 411, pp. 355- 365 ,(2001) , 10.1038/35077225
Vincent A. Pollack, Catherine DiOrio, April Theleman, Elsa G. Barbacci, Leslie R. Pustilnik, Mark Neveu, Mikel P. Moyer, Kenneth K. Iwata, Lee Arnold, Michael J. Morin, James D. Moyer, Bruce Boman, Penny Miller, Ann Cunningham, Margaret M. Reynolds, Don Sloan, Jonathan Doty, Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Research. ,vol. 57, pp. 4838- 4848 ,(1997)
D. Bossemeyer, R.A. Engh, V. Kinzel, H. Ponstingl, R. Huber, Phosphotransferase and substrate binding mechanism of the cAMP-dependent protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). The EMBO Journal. ,vol. 12, pp. 849- 859 ,(1993) , 10.1002/J.1460-2075.1993.TB05725.X
J.D. Winkler, P.A. Lee, E. Wallace, G. Poch, K. Litwiler, T. Pheneger, J. Lyssikatos, M. Perrier, S.G. Eckhardt, T.C. Yeh, 342 Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model Ejc Supplements. ,vol. 2, pp. 103- 104 ,(2004) , 10.1016/S1359-6349(04)80349-5
Aimee K. Bence, Eric B. Anderson, Maqbool A. Halepota, Michael A. Doukas, Phillip A. DeSimone, George A. Davis, Deborah A. Smith, Kevin M. Koch, Andrew G. Stead, Steve Mangum, Carolyn J. Bowen, Neil L. Spector, Showchien Hsieh, Val R. Adams, Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects Investigational New Drugs. ,vol. 23, pp. 39- 49 ,(2005) , 10.1023/B:DRUG.0000047104.45929.EA
Román Peréz-Soler, Leonard Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology. ,vol. 23, pp. 5235- 5246 ,(2005) , 10.1200/JCO.2005.00.6916
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609